glp 1 approved for mash The FDA has Wegovy (semaglutide) as a treatment metabolic-associated steatohepatitis (MASH) with moderate-to-advanced scarring, a serious liver condition affecting approximately 6% of US adults. Key highlights of drug development program Emerging Role of GLP-1 Receptor

The meta-analysis included 21 trials (10 PIONEER and 11 SUSTAIN trials) involving 12,260 semaglutide users

Journal of the American Pharmacists Association, 64(1), 204211.

This medication category includes weekly injectables and daily oral pills: Semaglutide (Wegovy , Ozempic ) Tirzepatide (Zepbound , Mounjaro ) Orforglipron (Foundayo ) The FDA approves these specific brands for different uses: Wegovy , Zepbound , and Foundayo for weight management, and Ozempic and Mounjaro for type 2 diabetes

Important 2026 Update Because BCBS is a national federation of independent, locally operated companies, coverage can vary widely across states and plans